• Roscovitine (Seliciclib): Advancing CDK2 Inhibition in Trans

  2026-05-09

  This thought-leadership article explores the mechanistic foundation and translational impact of Roscovitine (Seliciclib, CYC202) as a selective cyclin-dependent kinase inhibitor. Integrating recent immuno-oncology advances and rigorous experimental validation, the piece offers strategic guidance for researchers leveraging cell cycle arrest and CDK2 pathway disruption to accelerate cancer biology research and refine combination therapies. The article extends beyond standard product summaries by bridging mechanistic insights with actionable workflow recommendations, referencing both foundational studies and the latest immunotherapy findings.

• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–Receptor Bi

  2026-05-08

  This study reveals that naturally occurring angiotensin peptides, including Angiotensin (1-7), enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor, with implications for COVID-19 pathogenesis. The findings suggest a novel cross-talk between the renin–angiotensin system and viral entry mechanisms, highlighting new avenues for translational research.

• VIK-Mediated Phosphorylation Regulates Lateral Root Emergenc

  2026-05-07

  This study uncovers a novel role for the kinase VIK in regulating auxin-induced lateral root development in Arabidopsis. By directly phosphorylating both positive and negative regulators of root emergence, VIK modulates protein stability and turnover, offering new mechanistic insight into root system architecture control.

• Restoring Tumor Suppression: PTEN mRNA for Translational Pro

  2026-05-07

  This article explores how in vitro transcribed, pseudouridine-modified EZ Cap™ Human PTEN mRNA (ψUTP) can strategically re-enable tumor suppressor function in translational cancer research. Integrating mechanistic insights, recent peer-reviewed breakthroughs, and best-practice guidance, it frames a forward-looking agenda for deploying mRNA reagents in the battle against therapy-resistant malignancies.

• YM-155 Hydrochloride: Optimizing Survivin Inhibitor Assays

  2026-05-06

  YM-155 hydrochloride delivers nanomolar precision as a survivin inhibitor, enabling robust investigation of apoptosis suppression across diverse cancer models. Discover actionable protocols, advanced use-cases, and troubleshooting strategies to unlock its full potential in vitro and in vivo.

• Technical Guide: Anti-HMGB1 Rabbit Monoclonal Antibody (MA30

  2026-05-06

  The Anti-HMGB1 Rabbit Monoclonal Antibody (MA3057) offers researchers a validated tool for the detection of HMGB1 protein in human, mouse, and rat samples across Western blot, immunohistochemistry, and flow cytometry workflows. It should be used strictly for scientific research and is not validated for diagnostic or therapeutic purposes.

• Triiodothyronine (T3): Enabling Translational Breakthroughs

  2026-05-05

  This thought-leadership article explores the mechanistic and translational potential of Triiodothyronine (T3) in the context of adipocyte thermogenesis, integrating recent findings from SEMA3E research and strategic product guidance for advanced metabolic disorder studies. It addresses experimental design, protocol rigor, and competitive selection, positioning APExBIO’s high-purity T3 as an indispensable tool for modern translational researchers.

• YAP-TEAD Regulation of Super-Enhancers in Ectoderm Commitmen

  2026-05-05

  Wang et al. (2026) demonstrate that the YAP-TEAD transcriptional complex orchestrates the super-enhancer (SE) network to guide early surface ectoderm specification from pluripotent stem cells. Integrating 3D genomics, histone profiling, and CRISPR perturbations, this work refines the mechanistic understanding of lineage commitment, offering new directions for regenerative medicine and epithelial tissue engineering.

• Prednisone in Bench Research: Protocols, Optimization & Trou

  2026-05-04

  Prednisone, a synthetic corticosteroid from APExBIO, enables precise immunosuppression and apoptosis induction in translational research workflows. This guide delivers actionable protocol enhancements, troubleshooting strategies, and data-driven insights for researchers leveraging Prednisone in immunology, neurodegeneration, and apoptosis models.

• HDAC Inhibitors as NUT Function Repressors in NUT Carcinoma

  2026-05-04

  Shiota et al. conducted a robust chemical screen that identified diverse and novel histone deacetylase (HDAC) inhibitors as potent repressors of NUT function in NUT carcinoma cells. Their work reveals mechanistic underpinnings of transcriptional reprogramming in this aggressive cancer, highlighting HDAC inhibition as a promising therapeutic axis for targeting oncogenic megadomains and restoring differentiation.

• Bestatin (Ubenimex): Applied Protocols in Aminopeptidase and

  2026-05-03

  Bestatin (Ubenimex) is a potent, selective aminopeptidase inhibitor central to apoptosis, multidrug resistance, and cancer research workflows. This article details protocol optimization, advanced troubleshooting, and translational use-cases that leverage APExBIO's high-purity offering for robust, reproducible results.

• Triiodothyronine (T3): Ensuring Reproducibility in Cell Assa

  2026-05-02

  This article addresses persistent challenges in cell viability and metabolic assays by detailing how high-purity Triiodothyronine (SKU C6407) supports rigorous, reproducible research. Through scenario-driven guidance, researchers gain actionable insights on protocol optimization, data interpretation, and vendor selection—grounded in validated product specifications and current literature.

• α7nAChR-Driven Endothelial Pyroptosis in HIV-1 gp120 BBB Inj

  2026-05-02

  This study uncovers a novel mechanism by which HIV-1 gp120 directly induces pyroptosis in brain endothelial cells via an α7 nicotinic acetylcholine receptor (α7nAChR)-dependent pathway, leading to blood–brain barrier (BBB) disruption. The findings highlight an unexpected pathogenic role for α7nAChR and demonstrate that clinically approved drugs, memantine and metformin, can synergistically block this process, opening translational opportunities for HIV-associated neurocognitive disorder (HAND) intervention.

• JHU-083: Advancing Glutaminase Pathway Research in Neurology

  2026-05-01

  JHU-083 streamlines glutaminase pathway research by offering selective, high-purity antagonism, uniquely suited for neurological disease models and glutamate excitotoxicity studies. Its robust solubility and reliable targeting of cerebral CD11b cells make it an essential tool for experimental cerebral malaria and beyond.

• Two Decades of Toremifene Citrate in Breast Cancer Therapy

  2026-04-30

  This review synthesizes twenty years of clinical and mechanistic data on Toremifene Citrate, highlighting its role as an oral selective estrogen receptor modulator in the management of hormone receptor-positive breast cancer. The findings support its efficacy, nuanced tissue selectivity, and pharmacokinetic distinctions from other SERMs, with implications for both experimental and clinical research.

16806 records 1/1121 page Next 12345 下5页 Last page